Margi Bhatt, MD
Hospitalist · Salt Lake City, UTNPI 1174594485
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$458
- Boehringer Ingelheim$435
- Astellas Pharma US Inc$363
- Lilly USA, LLC$282
- AbbVie$215
- Amgen$215
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,832100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 33 | $458 |
| Boehringer Ingelheim | 23 | $435 |
| Astellas Pharma US Inc | 23 | $363 |
| Lilly USA, LLC | 17 | $282 |
| AbbVie(2 entities) | 12 | $215 |
| Amgen | 15 | $215 |
| Sanofi-aventis U.S. LLC | 14 | $201 |
| Abbott | 16 | $178 |
| GSK | 11 | $177 |
| Gilead | 8 | $165 |
| Dexcom, Inc. | 7 | $144 |
| Novartis | 7 | $128 |
| Pfizer | 7 | $105 |
| Johnson & Johnson(2 entities) | 6 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Novo Nordisk | 4 | $53 |
| Lifescan, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Boston Scientific | 3 | $45 |
| Lucid Diagnostics Inc. | 3 | $43 |
| Edwards Lifesciences | 2 | $42 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Bayer | 2 | $31 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Viiv Healthcare Company | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Medtronic | 1 | $17 |
| Insmed, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
How this compares
$3,844 in reported general payments places this provider in the 95th percentile of 203 hospitalist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $54,597 |
| OzempicSemaglutide | 22 | $46,794 |
| MounjaroTirzepatide | 26 | $29,805 |
| MyrbetriqMirabegron | 29 | $19,658 |
| TrulicityDulaglutide | 11 | $10,549 |
| JardianceEmpagliflozin | 14 | $8,917 |
| JanuviaSitagliptin Phosphate | 12 | $6,657 |
| Rosuvastatin Calcium | 188 | $2,142 |
| Ezetimibe | 45 | $1,594 |
| Triazolam | 13 | $1,459 |
| Bupropion XlBupropion Hcl | 21 | $1,286 |
| SynthroidLevothyroxine Sodium | 16 | $1,131 |
| Levothyroxine Sodium | 113 | $1,039 |
| Escitalopram Oxalate | 67 | $1,008 |
| Methenamine Hippurate | 17 | $955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $105 | $54,59763 claims |
| Novo NordiskOzempic | $53 | $46,79422 claims |
| Lilly USA, LLCMounjaro, Trulicity | $282 | $40,35437 claims |
| Astellas Pharma US IncMyrbetriq | $363 | $19,65829 claims |
| Boehringer IngelheimJardiance | $435 | $8,91714 claims |
| MerckJanuvia | $458 | $6,65712 claims |
| AbbVieSynthroid | $215 | $1,13116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 hospitalist providers in Utah.
Other hospitalist in Salt Lake City
- Mark KellySalt Lake City$7K
- Beth HanlonSalt Lake City$3K
- Victoria WilkinsSalt Lake City$2K
- Valerie VaughnSalt Lake City$2K
- Michelle HofmannSalt Lake City$955
- Ryan BenderSalt Lake City$648
- Kena DesaiSalt Lake City$592
- Carlos CuevaSalt Lake City$447
- Matthew SiegelSalt Lake City$424
- Donald NoSalt Lake City$395
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.